Home » Proctology » Allergan enters into agreement to acquire Aquesys and its XEN45 program Allergan plc.

Dominic ffytcheMatricellular proteins may be important therapeutic targets for common ocular disordersNovartis announces FDA approval of dual combination bronchodilator Utibron Neohaler for COPD individuals Using its pedigree in the eye treatment space, its deep industrial network in eye treatment professional communities, and its own commitment to being a leading service provider of treatments for glaucoma, Allergan was an all natural fit and a compelling partner for us to maximize the potential for the XEN45 technology platform, said Ron Bache, CEO of AqueSys. The addition of the XEN45 technology to Allergan's world-class eyes care development and commercialization organization can propel the potential usage of this best-in-class technology by global ophthalmologists and the sufferers that they deal with.Study Oversight The protocol, available with the full text of the article at NEJM.org, was approved by the institutional review plank in each site, and the analysis was conducted relative to the provisions of the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice recommendations. All the patients provided written knowledgeable consent before research entry. The first author and the last writer were in charge of oversight of the study. Merck donated the analysis medication and reviewed the final drafts of the protocol and of this manuscript before submission; they didn’t participate in the evaluation of the data. The study agent, pembrolizumab, was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days .